Life Science Investing New Data at the Asia Pacific Heart Rhythm Society 2025 Highlight the Performance of iRhythm's Zio Long-Term Continuous Monitoring in an Asian Population
Life Science Investing Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease
Life Science Investing Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
Life Science Investing NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
Life Science Investing Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.
Life Science Investing Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Life Science Investing Acadia Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
Life Science Investing Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
Life Science Investing Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study
Life Science Investing Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
Life Science Investing Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Life Science Investing Quantum-Si Highlights Significant Development Advancements for Proteus and Industry Leading Technology Pipeline at Investor & Analyst Day
Life Science Investing Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer's Disease Conference
